NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARVN shares have decreased by 18.5% and is now trading at $35.92. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) released its quarterly earnings results on Tuesday, April, 28th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. The firm earned $6.24 million during the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative return on equity of 30.74% and a negative net margin of 171.74%. View Arvinas' earnings history.

11 Wall Street analysts have issued 1 year target prices for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they expect Arvinas' share price to reach $57.10 in the next year. This suggests a possible upside of 59.0% from the stock's current price. View analysts' price targets for Arvinas.

News articles about ARVN stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arvinas earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near term. View the latest news aboutArvinas.

Arvinas saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 2,570,000 shares, a drop of 11.4% from the April 30th total of 2,900,000 shares. Based on an average daily volume of 401,000 shares, the short-interest ratio is presently 6.4 days. Currently, 10.1% of the company's shares are short sold. View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), PPD (SDGR), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Biohaven Pharmaceutical (BHVN), Blueprint Medicines (BPMC) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.56%), 5AM Venture Management LLC (2.55%), Orbimed Advisors LLC (2.54%), State Street Corp (1.21%), ArrowMark Colorado Holdings LLC (0.97%) and Rock Springs Capital Management LP (0.73%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, 5AM Venture Management LLC, Ghost Tree Capital LLC, Pictet Asset Management Ltd., Spark Investment Management LLC, Citigroup Inc., Sphera Funds Management LTD., and UBS Group AG. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Sean A Cassidy, and Ventures Iii LP 5Am. View insider buying and selling activity for Arvinas.

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Federated Hermes Inc., Two Sigma Advisers LP, AQR Capital Management LLC, Rock Springs Capital Management LP, State Street Corp, Schroder Investment Management Group, and Castleark Management LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon. View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $35.92.

Arvinas has a market capitalization of $1.41 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]